AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21812261
Drug: Madopar (basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar (basic treatment) + BHG
Trial: 21812261
Drug: Madopar (basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar (basic treatment) + Placebo
Trial: 15496639
Drug: Fluvoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 50 mg daily for 6 days
Trial: 12966817
Drug: Manually guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually guided exposure therapy in virtual environments
Trial: 1929099
Drug: Estriol vaginal
RxNorm normalized name: estriol Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol vaginal cream
Trial: 1929099
Drug: Trazodone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone and Estriol vaginal cream
Trial: 19713253
Drug: Repetitive paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive paravertebral injections with a mixture of 10 mL 0.25% bupivacaine and 40 mg methylprednisolone acetate every 48 h for a week
Trial: 19713253
Drug: Repetitive paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive paravertebral injections with local anesthetics and steroids
Trial: 19713253
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (paravertebral and standard therapy)
Trial: 17124578
Drug: Terbinafine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 150 mg daily for 6 days
Trial: 15225946
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g with codeine 60 mg
Trial: 15225946
Drug: Placebo (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Vitamin C 50 mg)
Trial: 11172189
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with supplemental oxygen and no ventilatory support
Trial: 21233425
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements and parental counseling
Trial: 20420791
Drug: Toprel 100
RxNorm normalized name: metoprolol succinate 100 MG [Toprol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toprel 100 mg
Trial: 20420791
Drug: Topamax 100
RxNorm normalized name: Topamax 100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topamax 100 mg
Trial: 17084803
Drug: Lutein (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (10 or 20 mg/day)
Trial: 17084803
Drug: Lutein +
RxNorm normalized name: Lutein + Kale
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein + Zeaxanthin (10 or 20 mg/day)
Trial: 17084803
Drug: Zeaxanthin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zeaxanthin (10 or 20 mg/day)
Trial: 12141769
Drug: Antibiotic packing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic packing (cotton gauze strips with polymyxin‐B‐sulfate and oxytetracycline ointment)
Trial: 12141769
Drug: Antibiotic-free packing
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-free packing (polyvinyl acetate sponge and cotton gauze strips with sea‐salt ointment)
Trial: 10199248
Drug: Active epidural
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active epidural analgesic paste
Trial: 2304838
Drug: Project nurse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Project nurse intervention involving daily hospital visits, coordination of discharge planning, and home visits post-discharge.
Trial: 6992902
Drug: Salbutamol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (6 mg/day)
Trial: 31187424
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg/kg IV followed by 0.5 µg/kg/h infusion during surgery)
Trial: 31187424
Drug: Saline (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (same doses as DEX)
Trial: 22829349
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of spontaneous pushing plus perineal massage
Trial: 19948625
Drug: Aripiprazole (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5, 10, or 15 mg/day)
Trial: 11772231
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy administered for six months after surgery for Dukes C colon cancer
Trial: 11772231
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy for advanced CRC
Trial: 3148145
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg triazolam on nights N3, N4, N5
Trial: 3148145
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg triazolam on nights N3, N4, N5
Trial: 21092614
Drug: Electrical acupuncture
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical acupuncture stimulation therapy combined with pelvic floor muscle therapy (PFMT)
Trial: 22366878
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (80% of maximum) twice weekly for 10 weeks
Trial: 12162755
Drug: Filgrastim (granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (granulocyte colony‐stimulating factor, G‐CSF)
Trial: 2540141
Drug: Progestin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin (20 mg tid medroxyprogesterone acetate)
Trial: 2540141
Drug: Estrogen (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (1.25 mg bid conjugated equine estrogens)
Trial: 30695422
Drug: Muxiang Shunqi
RxNorm normalized name: Tumuxiang (Inula Helenium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muxiang Shunqi Pill (MSP), 6 g each time, three times per day, taken 30 min after dinner for 4 weeks
Trial: 30695422
Drug: Mosapride Tablet
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride Tablet (MT), 5 mg each time, three times per day, taken 30 min before dinner for 4 weeks
Trial: 23083839
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg (additional dose)
Trial: 15261707
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or venlafaxine
Trial: 11292002
Drug: ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (4 microg/kg b.i.d.) + naltrexone (25 mg b.i.d.)
Trial: 9022118
Drug: 2.0% dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% dorzolamide (three times daily)
Trial: 9022118
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol (twice daily)
Trial: 9022118
Drug: 2.0% dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% dorzolamide (twice daily) added to 0.5% timolol
Trial: 7939393
Drug: Loxiglumide (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (1200 mg orally)
Trial: 30646253
Drug: ASSIP intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASSIP intervention (3 manual-based therapy sessions followed by regular personalized letters over 24 months)
Trial: 26480931
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (DXM) 40 mg/d for 4 days
Trial: 26480931
Drug: Prednisone (PDN)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PDN) 1.0 mg/kg daily for 4 weeks
Trial: 24670122
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 200 mg daily for 12 weeks
Trial: 24670122
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 400 mg daily for 12 weeks
Trial: 24670122
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 600 mg daily for 12 weeks
Trial: 24670122
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 800 mg daily for 12 weeks
Trial: 18622420
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and peripheral stem-cell reinfusion
Trial: 18622420
Drug: Using the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the catheter for both stem-cell apheresis and high-dose chemotherapy
Trial: 18622420
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of total parenteral nutrition (TPN)
Trial: 31302440
Drug: ECT (Electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT (Electroconvulsive Therapy)
Trial: 11031332
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS; 400 microg, twice daily)
Trial: 11031332
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray (twice daily)
Trial: 1468091
Drug: Cefadroxil monohydrate
RxNorm normalized name: Cefadroxil Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil monohydrate (30 mg/kg QD or 15 mg/kg BID)
Trial: 3740024
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol electrolyte gut lavage solution (old, n=105)
Trial: 29393079
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (sterile 90% ethanol)
Trial: 24796048
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (acupuncture, moxibustion, and modified Mojie tablet)
Trial: 24796048
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (gestrinone 2.5 mg, once a day, twice a week)
Trial: 24796048
Drug: Other groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other groups (acupuncture‐moxibustion and combined therapy)
Trial: 21934156
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection targeting certain months (e.g., May)
Trial: 18647523
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 8 grams daily
Trial: 18647523
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (GSH) 1.2 grams daily
Trial: 11164155
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant hormonal treatment (NHT)
Trial: 11164155
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of neoadjuvant hormonal treatment (NHT)
Trial: 9200377
Drug: Dual regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual regimen (omeprazole 0.6 mg/kg twice a day + amoxicillin 30 mg/kg twice a day)
Trial: 9200377
Drug: Triple regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple regimen (dual regimen + clarithromycin 15 mg/kg twice a day)
Trial: 9200377
Drug: Active ulcers
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ulcers treatment
Trial: 8477407
Drug: apomorphine injection
RxNorm normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: apomorphine injection (first and second injections)
Trial: 8477407
Drug: apomorphine injection
RxNorm normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: apomorphine injection (second injection administered 10 or 80 min after first)
Trial: 8477407
Drug: apomorphine injection
RxNorm normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: apomorphine injection (second administration)
Trial: 3630589
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg kg‐1 diazepam orally with 100 ml of water 2 h before surgery (Group 100)
Trial: 3630589
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg kg‐1 diazepam with 50 ml of water 2 h before surgery (Group 50)
Trial: 25851421
Drug: HG broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HG broccoli diet (400 g per week for 12 weeks)
Trial: 25851421
Drug: Standard broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard broccoli diet (400 g per week for 12 weeks)
Trial: 21114369
Drug: Sildenafil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (40 mg oral dose)
Trial: 21114369
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1, alprostadil 200 ng · kg(‐1) · min(‐1) intravenous infusion)
Trial: 19683591
Drug: SFC+LTRA (pranlukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC+LTRA (pranlukast 450 mg daily)
Trial: 19683591
Drug: SFC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC therapy alone
Trial: 15223852
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg flutamide once daily
Trial: 15223852
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg flutamide twice daily
Trial: 15223852
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg flutamide 3 times daily
Trial: 15223852
Drug: Flutamide at
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide at 500 mg daily
Trial: 11422007
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg single dose
Trial: 9639751
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg ethinyl estradiol (EE)
Trial: 9639751
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg ethinyl estradiol (EE)
Trial: 8481662
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside (3.0 g/m2 for < 60 years; 1.0 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Trial: 8481662
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose cytosine arabinoside (1.0 g/m2 for < 60 years; 0.5 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Trial: 8481662
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose cytosine arabinoside
Trial: 3318445
Drug: S-adenosylmethionine (SAMe)
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosylmethionine (SAMe) 1,200 mg
Trial: 23922258
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy (VT)
Trial: 31619350
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no vibration therapy)
Trial: 30033595
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg once or twice daily
Trial: 23072079
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (conventional acupuncture at Tianshu, Zusanli, Shangjuxu, Sanyinjiao, Taichong with electric stimulation at bilateral Tianshu), 3-4 treatments per week for 4 weeks.
Trial: 23072079
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Pinaverium, 50 mg orally, 3 times a day for 4 weeks).
Trial: 24503140
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg)
Trial: 11115818
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of lipid
Trial: 9695140
Drug: Naloxone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.0 mg/kg)
Trial: 7981009
Drug: Nadolol 5
RxNorm normalized name: bendroflumethiazide-nadolol 5 mg-40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 5 mg (N5)
Trial: 7981009
Drug: Nadolol 20
RxNorm normalized name: nadolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 20 mg (N20)
Trial: 7981009
Drug: Nadolol 80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 80 mg (N80)
Trial: 29386337
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) as an add-on to standard PR programme
Trial: 18410636
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid booster (TTB) immunization, administered to 52 participants (15 from PI-sparing, 37 from PI-containing) at median 25 weeks after HAART initiation.
Trial: 18410636
Drug: No TTB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TTB immunization, administered to 23 participants (6 from PI-sparing, 17 from PI-containing).
Trial: 12204508
Drug: felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine (5 mg)
Trial: 12204508
Drug: metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (50 mg)
Trial: 12204508
Drug: enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (10 mg)
Trial: 12204508
Drug: clinically prescribed
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinically prescribed medications
Trial: 11151867
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg once daily), amoxicillin (1 g b.i.d.), and clarithromycin (500 mg b.i.d.) (EAC)
Trial: 11151867
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg once daily), clarithromycin (500 mg twice daily) (EC)
Trial: 11151867
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg once daily) (E)
Trial: 11151867
Drug: Emergent resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergent resistance after treatment with EAC
Trial: 8807099
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion GM‐CSF (GM‐CSF (CI))
Trial: 8807099
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion GM‐CSF followed by sequential G‐CSF (GM‐CSF/G‐CSF)
Trial: 8807099
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control patients receiving GM‐CSF as a 2‐h intravenous infusion (GM‐CSF (2‐h))
Trial: 8807099
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion GM‐CSF (GM‐CSF (CI)) and GM‐CSF/G‐CSF
Trial: 1581405
Drug: rhGM-CSF at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF at a daily dose of 108 micrograms (group I)
Trial: 1581405
Drug: rhGM-CSF at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF at a daily dose of 216 micrograms (group II)
Trial: 1581405
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of treatment
Trial: 18034989
Drug: Amlodipine (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5‐10 mg)
Trial: 31152476
Drug: everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI)
Trial: 27645834
Drug: CBT-I (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-I (Cognitive Behavior Therapy for Insomnia)